Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...
Clinical Trials Arena on MSN1d
Amgen’s gMG therapy cuts disease symptoms at one-year markResults from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...
Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).
In myasthenia gravis, the receptors for acetylcholine at the muscle surface are destroyed or modulated by antibodies that prevent the normal reaction from occurring. The antibodies are produced by the ...
Imagine a world where worms can hear. While it may sound like science fiction, researchers at the University of Michigan have discovered that the nematode C. elegans, a commonly studied model organism ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback